Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.837
-0.024 (-2.81%)
At close: Apr 28, 2026, 4:00 PM EDT
0.837
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Aprea Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.29 | 1.5 | 0.58 | - | - | |
| Revenue Growth (YoY) | -80.98% | 157.63% | - | - | - | |
| Cost of Revenue | 7.04 | 9.36 | 7.63 | 16.4 | 23.9 | |
| Gross Profit | -6.76 | -7.86 | -7.04 | -16.4 | -23.9 | |
| Selling, General & Admin | 6.48 | 6.46 | 8.43 | 20.97 | 13.55 | |
| Operating Expenses | 6.48 | 6.46 | 8.43 | 20.97 | 13.55 | |
| Operating Income | -13.23 | -14.32 | -15.47 | -37.37 | -37.45 | |
| Interest & Investment Income | 0.65 | 1.29 | 1.22 | 0.45 | 0 | |
| Currency Exchange Gain (Loss) | -0.1 | 0.07 | -0.04 | 0.28 | 0.32 | |
| Other Non Operating Income (Expenses) | 0.08 | - | - | - | - | |
| EBT Excluding Unusual Items | -12.6 | -12.96 | -14.29 | -36.64 | -37.13 | |
| Pretax Income | -12.6 | -12.96 | -14.29 | -112.66 | -37.13 | |
| Net Income | -12.6 | -12.96 | -14.29 | -112.66 | -37.13 | |
| Net Income to Common | -12.6 | -12.96 | -14.29 | -112.66 | -37.13 | |
| Shares Outstanding (Basic) | 7 | 6 | 4 | 2 | 1 | |
| Shares Outstanding (Diluted) | 7 | 6 | 4 | 2 | 1 | |
| Shares Change (YoY) | 18.67% | 52.31% | 118.31% | 55.69% | 0.72% | |
| EPS (Basic) | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | |
| EPS (Diluted) | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | |
| Free Cash Flow | -12.89 | -13.57 | -12.27 | -25.01 | -37.69 | |
| Free Cash Flow Per Share | -1.97 | -2.46 | -3.39 | -15.09 | -35.41 | |
| Operating Margin | -4631.12% | -953.00% | -2652.80% | - | - | |
| Profit Margin | -4409.16% | -862.43% | -2449.59% | - | - | |
| Free Cash Flow Margin | -4512.35% | -903.26% | -2103.92% | - | - | |
| EBITDA | -13.21 | -14.3 | -15.46 | -37.37 | -37.43 | |
| D&A For EBITDA | 0.02 | 0.02 | 0.01 | 0 | 0.01 | |
| EBIT | -13.23 | -14.32 | -15.47 | -37.37 | -37.45 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.